Clinical Trials Browser

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

Clinical Trials

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

PALANGI3

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

Neoadjuvant Tebentafusp for Uveal Melanoma

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

O-Mel-Sora

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

PROMPT

DIET

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

Psychoeducation for Uveal Melanoma

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors